RA Topic Center Upper Left Box

Biologics and DMARDs are hailed as miracles and almost-cures for rheumatoid arthritis, if you can catch the patient quickly enough. But Jon Lampa MD of Karolinska Hospital in Sweden has noticed that many studies use inflammation, not pain relief, as their criterion for success.

 

WHEN RA TREATMENT
FALLS SHORT





Biologics and DMARDs are hailed as miracles and almost-cures for rheumatoid arthritis, if you can catch the patient quickly enough. But Jon Lampa MD of Karolinska Hospital in Sweden has noticed that many studies use inflammation, not pain relief, as their criterion for success.


So: How many patients "adequately" treated for RA continue to suffer pain nonetheless? He and his coworkers decided to look at the magnitude of the problem, with noteworthy results.
 

It's time to pay more attention to pain from baseline, he says in this brief video, and to find ways to do something about it when the best modern treatments don't.


See Big Flaw in RA Treatment Success Record: Remaining Pain.


 

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.